By measuring the surface-enhanced Raman spectra (SERS) of various low concentrations of platelet-derived growth factor-BB (PDGF-BB) aqueous solution, the Raman characteristic peak at Raman shift of 1509 cm-1 can be detected for PDGF-BB aqueous solution with mass fraction as low as 10-8. By detecting SERS of urine samples of the preoperative patient who has higher degree of atherosclerosis and is treated with percutaneous coronary intervention (PCI) and the patient who has lower degree of atherosclerosis and is not treated with PCI, as well as the Raman characteristic peak of PDGF-BB at Raman shift of 1509 cm-1, we find that the peak at 1509 cm-1 can be detected on the SERS of the patient with PCI, which reveals that the concentration of PDGF-BB in urine is correlative with the degree of atherosclerosis. The results show that the low concentration of aqueous solution of PDGF-BB can be detected by SERS technology, and the SERS of urine sample can be used to determine whether the patients with coronary heart disease need to have PCI. Hence, the technology will be a clinical diagnostic tool for non-destructive testing and screening coronary heart disease.